7th RNA-Targeted Drug Discovery & Development Summit

Optimizing Lead Discovery, Structural Analysis & Preclinical Modeling to Successfully Develop Stable, Effective & Orally Bioavailable Small Molecule RNA Drugs for Robust Translation into the Clinic

With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins and RNA/protein complexes.

Hence, as the go-to meeting for the RNA-targeting small molecule the community, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures, delve into innovative preclinical modelling strategies and identify optimal chemical features for advancing specific, efficacious and safe small molecules.

Unite with 100+ RNA Science, Medicinal Chemistry, Structural Biology & Biophysics experts from the likes of AstraZeneca, Sanofi, Novartis, PTC Therapeutics, ReviR Therapeutics, Rgenta Therapeutics, Accent Therapeutics and more at the most comprehensive and definitive event for the community, the 7th RNA-Targeted Drug Discovery & Development Summit, to accomplish faster and smoother translation of RNA targeted therapies towards the clinic.

Dates: December 10-12, 2024

Location: Hilton Boston Back Bay, Boston, MA

Event Program: https://ter.li/zpqueo

New and Noteworthy Sessions:

• “Utilizing RNA-Seq Data At-Scale to Improve the Translatability of mRNA Splicing Modulators”
  Steve Lianoglou, Director, Translational Genomics, ReviR Therapeutics
• "Large-Scale Discovery of RNA Tertiary Structures & Disease Relevant RNA Targets”
  Kevin Weeks, Kenan Distinguished Professor, University of North Carolina at Chapel Hill
• “Showcasing Insights to A-Bulge Splice Modulator Selectivity Derived from Studies of Minigenes & Other Genetic Instruments”
  Joon Lee, Associate Scientific Director, Biogen
• “Leveraging Strategies to Drug RNA-Protein Complexes with Small Molecules to Drive More Novel Therapeutics Towards the Clinic”
  Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics
• “Fireside Chat - Discussing Investment in RNA-Targeting Therapeutics to Accelerate Advancement of Small Molecule Therapies for Patients in Need”
  Joy Ghosh, Managing Director, Abingworth
  Yang Zheng, Head, Business Development, Base4 Biotechnology

Download the agenda here: https://ter.li/zpqueo

Register your place here (and take advantage of group discounts of up to 20% when sending your team of two or more!): https://ter.li/witb2w